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2978 JOURNABSTRACT: The selection and discovery of new crystalline forms is a longstanding issue
in solid-state chemistry of critical importance because of the effect molecular packing
arrangement exerts on materials properties. Polymer-induced heteronucleation has
recently been developed as a powerful approach to discover and control the production of
crystal modifications based on the insoluble polymer heteronucleant added to the
crystallization solution. The selective nucleation and discovery of new crystal forms
of the well-studied pharmaceuticals flurbiprofen (FBP) and sulindac (SUL) has been
achieved utilizing this approach. For the first time, FBP form III was produced in bulk
quantities and its crystal structure was also determined. Furthermore, a novel 3:2
FBP:H2O phase was discovered that nucleates selectively from only a few polymers.
Crystallization of SUL in the presence of insoluble polymers facilitated the growth of
form I single crystals suitable for structure determination. Additionally, a new SUL
polymorph (form IV) was discovered by this method. The crystal forms of FBP and SUL
are characterized by Raman and FTIR spectroscopies, X-ray diffraction, and differential
scanning calorimetry.  2007 Wiley-Liss, Inc. and the American Pharmacists Association
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solid-state stabilityINTRODUCTION
Research activity seeking methodology for con-
trolling the production of a given solid phase has
drastically increased in recent years, in large part
due to intellectual property rights and quality
control regulations in the pharmaceutical indus-
try.1–3 Crystal polymorphism can have a profound
effect on solid-state properties and, because of
potential differences in bioavailablity, is of key
importance in the manufacture of drugs. Tradi-
tional methods of controlling the phenomenon of
polymorphism,4–6 including modification of crys-nce to: Adam J. Matzger (Telephone: 734-615-
615-8553; E-mail: matzger@umich.edu)
aceutical Sciences, Vol. 96, 2978–2986 (2007)
, Inc. and the American Pharmacists Association
AL OF PHARMACEUTICAL SCIENCES, VOL. 96, NO. 11, NOtallization conditions, such as changing solvent,
temperature of crystallization, extent of super-
saturation, or melt crystallization, are often not
efficient at discovering new polymorphs or con-
trolling phase production. However, several
recent methods have proven effective in selective
production of known forms.7–17 Moreover, the
polymer-induced heteronucleation approach has
been successful in the discovery of novel pharma-
ceutical polymorphs and has also facilitated the
growth of single crystals of small molecules,16,17
extended networks,18 and inorganic complexes19
directly in the presence of insoluble polymers.
This is highly desirable for structure determina-
tion of both stable and metastable polymorphs
because it sheds light on the intermolecular
interactions stabilizing the crystal structure and
gives unambiguous proof of the existence of a newVEMBER 2007
NEW FORM DISCOVERY FOR FLURBIPROFEN AND SULINDAC 2979crystal form. A self-consistent set of spectroscopic,
calorimetric, and powder X-ray diffraction
(PXRD) data can then be correlated with the
corresponding structure allowing more accurate
phase identification during manufacture.
The polymorphism of flurbiprofen (FBP) and
sulindac (SUL) has been studied for decades
yielding three polymorphs of each drug.20–24 In
the case of FBP, two polymorphs are stable at
ambient conditions, while the other is reported to
be stable only when crystallized between a cover
slip and glass slide or in an aluminum pan.22
Furthermore, only the crystal structure of FBP
form I has been determined.25 Similarly, of the
three SUL polymorphs, all of which are reported
to be stable at ambient conditions,23,24 the crystal
structure of only form II has been elucidated.26 In
this case, the structure determined is actually of
the thermally less stable form II and the data are
not of sufficient quality for accurately character-
izing key intermolecular interactions. Here the
crystallization of the two polymorphic pharma-
ceuticals FBP and SUL is examined utilizing the
polymer-induced heteronucleation approach to
demonstrate its utility in producing new crystal-
line forms and single crystals suitable for struc-
tural characterization.EXPERIMENTAL
Materials
Commercial FBP (TCI, Portland, OH) and SUL
(Sigma, St. Louis, MO) were used as supplied.
Solvents, purchased from Fisher Scientific (Fair-
lawn, NJ) with the exception of ethanol (Pharmco
Products, Inc., Brookfield, CT), were used directly.
Commercial polymers were purchased from Scien-
tific Polymer Products, Inc. (Ontario, NY).Crystallization of FBP and SUL
FBP (300 mg) was dissolved in methanol (15 mL),
ethanol (15 mL), ethyl acetate (15 mL) aceto-
nitrile (15 mL), 2-propanol (15 mL), and heptane
(200 mg/15 mL with heating) and the entire
solution dispensed evenly among the 96 wells of a
microtiter plate, each of which contained a few
milligram of a single polymer. SUL (100 mg) was
dissolved in methanol (10 or 15 mL), ethanol
(15 mL), acetone (15 mL), chloroform (15 mL),
ethyl acetate (15 mL with heating), acetonitrile
(20 mL with heating), and 2-propanol (15 mL withDOI 10.1002/jps JOURNAheating) and the entire solution was dispensed as
described above. For solutions that required
heating for dissolution, the solution was cooled
to room temperature prior to dispensing and no
crystallization was observed upon cooling. Crys-
tallization proceeded upon evaporation of the
solvent at room temperature under a crystallizing
dish. A library of commercial polymers was
employed to maximize heteronucleant diversity
and results are only reported for those crystalliza-
tions in which the polymer did not dissolve to an
appreciable extent, in order to favor a hetero-
nucleation mechanism of crystal form production.X-Ray Diffraction
Single crystal X-ray diffraction data were
recorded on a Bruker SMART 1K CCD-based
X-ray diffractometer equipped with an LT-2 low
temperature device and normal focus Mo-target
X-ray tube (l¼ 0.71073 Å) operated at 2000 W
power (50 kV, 40 mA). Data were corrected for
absorption and the structures were solved and
refined using the Bruker SHELXTL software
package (version 6.12). All nonhydrogen atoms
were refined anisotropically with the hydrogen
atoms placed in idealized positions or located on a
difference map and allowed to refine. The crystal-
lographic data for SUL form I, FBP hydrate, and
FBP form III have been deposited with the
Cambridge Crystallographic Data Centre as
CCDC Nos. 625435, 625436, and 625437, respec-
tively. These data can be obtained free of charge
from the CCDC, 12 Union Road, Cambridge CB2
1EZ, UK (fax: þ44-1233-336033, e-mail: data_
request@ccdc.cam.ac.uk, or www.ccdc.cam.ac.uk/
products/csd/request).
PXRD was performed on a Rigaku R-Axis
Spider diffractometer equipped with a CuKa
source (l¼ 1.5406 Å) operated at 2000 W power
(50 kV, 40 mA) and an image plate detector.
Powder samples were mounted on a standard
goniometer head equipped with a Nylon loop and
affixedwith Apiezon-M grease. Typical scans were
30 min with v oscillating from 80 to 1408 at 18/sec,
w spinning at a rate of 108/sec, and x fixed at 308 to
remove the effects of preferred orientation.Vibrational Spectroscopy
Raman spectra were obtained using a Renishaw
inVia Raman Microscope equipped with a Leica
microscope, RenCam CCD detector, 785 nm diodeL OF PHARMACEUTICAL SCIENCES, VOL. 96, NO. 11, NOVEMBER 2007
2980 GRZESIAK AND MATZGERlaser, 1200 lines/mm grating, and 50 mm slit.
Spectra were collected in either extended scan
mode with a range of 100–3200 cm1 or static scan
mode centered at 420 cm1. Calibration was
performed using a silicon standard. Fourier
transform infrared (FTIR) spectra were collected
in transmission mode in KBr pellets utilizing a
Perkin-Elmer Spectrum BX FTIR system. The
scan range was 400–4000 cm1, using eight scans
per spectrum with a resolution of 2 cm1. Raman
spectroscopy of the KBr pellets confirmed that no
polymorphic transformation had occurred during
grinding or compression for the polymorphs
tested. Raman and FTIR spectra were analyzed
using the ACD/SpecManager (v8.11) software
package.Differential Scanning Calorimetry (DSC)
Thermograms of the samples were recorded on a
TA Instruments Q10 DSC. The thermal behavior
of the samples, placed in sealed aluminum pans,
was studied under a nitrogen purge with heating
rates of 58C/min, covering a temperature range
from 30 to 1308C for FBP and 40 to 2208C for SUL.
The instrument was calibrated with an indium
standard.Thermomicroscopy
Melting behavior was determined using a Mettler
Toledo FP82HT hot stage connected to an FP90
control processor and viewed under crossed
polarizers with a Leica DMLP microscope. Heat-
ing rates were typically 1.0 or 5.08C/min.Thermogravimetric Analysis (TGA)
Samples were heated from room temperature to
4008C in a nitrogen atmosphere at a rate of 108C/
min utilizing a TA Instruments Q50 TGA. The
instrument was calibrated with nickel and alumel
standards.Figure 1. Raman spectra of the crystal forms of
flurbiprofen.RESULTS AND DISCUSSION
Flurbiprofen
To explore the utility of the polymer-induced
heteronucleation approach for selectively crystal-
lizing polymorphs of the analgesic FBP and
facilitating single crystal growth, crystallizationJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 96, NO. 11, NOVEMBER 20was performed in the presence of polymer
heteronuclei. Raman spectroscopy of FBP crystals
revealed four distinct vibrational spectra during
high-throughput screening experiments. Three of
these were attributed to the known forms I–III of
FBP based on Raman spectroscopy, PXRD, and
melting behavior compared to results from pre-
vious literature characterization.20,22 The major-
ity of crystallizations in the presence of polymers
(>90%) resulted in the formation of form I with a
blade morphology. Form I has a characteristic
Raman spectrum (Fig. 1) with peaks at 219, 239,
284, 317, 419, 441, 474, 1128, 1295, and 1518 cm1
and FTIR spectrum with peaks at 575, 698, 766,
1129, 1324, and 1701 cm1, as well as PXRD
pattern with identifiable peaks at 2u¼ 7.1, 10.7,
16.4, 20.4, 23.4, and 29.78 (Fig. 2, Tab. 1). The
melting behavior of form I on the hot stage with a
heating rate of 58C/min revealed amelting point of
115.58C. DSC was performed to quantify the
melting behavior of form I and this revealed an
endotherm of melting with an onset temperature
of 115.0(2)8C and melting enthalpy of 29.1(4) kJ/
mol (Fig. 3, Tab. 2).
Needle-shaped form II crystals were identified
from several polymers including chlorosulfonated
polyethylene, polysulfone, and poly(vinyl alcohol)
from methanol solutions, 1,2-polybutadiene from
ethanol solutions, methyl vinyl ether/maleic acid
copolymer from 2-propanol solutions, and chlori-
nated polyethylene from acetonitrile solutions.
However, large quantities of form II were more
easily obtained by seeding supersaturated hex-
anes solutions with seed crystals grown directly
from polymers. This method was more reliable
than the literature method of crystallization of
supersaturated heptane solutions, which is07 DOI 10.1002/jps
Figure 2. PXRD patterns of the crystal forms of
flurbiprofen.
Table 1. PXRD Data for the Crystal Forms of Flurbiprofen and Sulindac
FBP form I FBP form II FBP form III FBP hydrate SUL form I SUL form II SUL form IV
2u (8) I/Io (%) 2u (8) I/Io (%) 2u (8) I/Io (%) 2u (8) I/Io (%) 2u (8) I/Io (%) 2u (8) I/Io (%) 2u (8) I/Io (%)
7.1 100 4.0 73.9 8.9 37.4 5.0 71.4 7.1 5.7 9.6 54.8 6.2 11.8
10.1 9.9 8.1 29.5 13.4 8.7 8.9 7.7 10.7 36.4 12.3 16.2 7.6 11.0
10.7 37.6 11.0 92.6 15.8 69.6 10.2 29.4 11.8 10.9 14.0 24.1 12.5 20.0
13.9 5.5 12.4 9.1 17.0 100 13.6 14.0 13.0 35.8 15.1 28.5 13.3 32.7
15.7 57.6 14.9 8.0 18.5 77.4 15.0 32.6 14.3 36.1 16.4 26.8 15.3 65.7
16.4 48.4 17.3 91.5 19.4 84.9 15.7 13.8 17.5 23.8 18.5 100 16.5 42.0
19.5 26.3 17.9 74.4 20.7 43.8 16.7 54.9 18.5 100 19.4 8.3 17.8 32.7
20.4 59.5 19.2 6.8 22.2 75.3 18.2 62.9 19.8 24.6 21.4 81.6 18.7 18.4
21.3 49.8 20.3 19.3 22.7 47.5 18.7 66.5 21.3 63.0 22.5 29.4 19.7 17.6
22.3 18.6 21.8 100 24.2 38.6 19.7 8.7 22.7 18.1 24.0 88.2 21.2 9.8
22.9 13.8 23.3 52.3 25.9 15.1 20.8 77.3 23.9 86.0 24.9 28.1 22.2 100
23.4 40.5 24.7 19.9 26.8 22.6 21.6 37.9 25.6 19.5 26.3 30.7 23.9 5.7
25.3 23.9 25.2 26.7 27.5 31.8 22.4 100 26.4 51.3 27.1 15.4 25.0 5.7
26.7 17.7 26.7 10.2 29.4 33.4 23.8 28.3 28.5 14.6 28.4 17.5 25.6 13.1
28.1 5.3 27.8 10.2 30.6 18.6 24.6 5.5 29.4 5.4 29.2 9.6 27.6 12.7
28.9 15.4 29.0 17.0 31.1 20.5 25.7 30.3 30.0 9.5 30.2 11.4 29.5 13.1
29.7 29.7 30.3 12.5 32.5 5.2 27.1 8.0 32.8 11.2 30.5 9.2 30.2 14.7
30.8 11.8 33.3 23.3 33.2 6.8 27.8 16.4 33.9 6.6 32.1 8.3 31.0 6.1
33.7 18.4 35.5 11.9 34.7 4.7 28.8 21.0 40.0 8.9 33.0 11.0 32.9 5.3
35.6 7.2 36.3 8.5 37.1 8.7 30.7 34.2 40.7 4.9 34.3 4.4 34.1 5.7
36.9 11.0 37.3 20.5 38.2 8.2 32.5 24.7 48.5 4.0 35.0 13.2 35.7 4.1
40.1 4.1 38.0 6.8 39.9 5.9 33.8 6.6 36.1 7.9 38.7 5.3
40.6 4.6 41.4 5.1 40.7 5.9 35.3 7.6 38.5 7.5
42.5 4.2 43.3 4.0 41.5 5.6 36.9 5.6 39.9 8.3
43.4 5.5 46.6 4.0 42.2 8.2 38.1 8.7 40.4 11.0
47.1 4.4 43.6 11.8 41.9 8.1 41.0 7.5
51.0 6.0 46.9 6.1 43.3 6.6 43.8 7.5
45.6 7.4 44.6 4.4
46.5 5.2 48.5 6.1
49.3 6.1
Figure 3. DSC thermograms of forms I, II, and III of
flurbiprofen.
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Table 2. Melting/Transition Temperature, Enthalpy of Transition, and Enthalpy of Melting for Flurbiprofen and
Sulindac Polymorphs
Onset of melting or transition (8C) DHtrans (kJ/mol) DHm (kJ/mol)
FBP form I 115.0 (2) – 29.1 (4)
FBP form II 91.5 (1) 0.28 (3) 28.1 (3)
FBP form III 55.3 (10) 2.9 (1) 22.4 (13)
SUL form I 190.6 (2) – 27.6 (1)
SUL form II 185.6 (1) – 31.1 (1)
SUL form IV 130.8 (31) – 21.4 (18)
2982 GRZESIAK AND MATZGERreported as ineffiecient.20 Form II was character-
ized by its distinct Raman spectrum with peaks at
221, 228, 299, 411, 452, 479, 1137, 1291, and
1515 cm1 and FTIR spectrum with peaks at 575,
701, 769, 1135, 1339, and 1711 cm1. Its PXRD
pattern exhibits characteristic diffraction
at 2u¼ 4.0, 11.0, 17.3, 17.9, 21.8, and 23.38 and
DSC reveals a 0.28(3) kcal/mol, overall exothermic
event with an onset temperature of 91.5(1)8C.
This transition corresponds to form II melting and
the simultaneous crystallization of form I, which
then melts at its expected temperature. This
process was confirmed by thermomicroscopy
where a transformation was observed between
90 and 968C and subsequent melting at 115.08C,
which is consistent with form I melting. Raman
microscopy of a sample heated to 1008C to allow
completion of the transition revealed that the
crystal had transformed to form I. The enthalpy of
melting of form II was determined to be 28.1(3) kJ/
mol and application of the heat-of-transition
rule27 reveals a monotropic relationship between
forms I and II.
Crystallization of form III, originally reported to
be stable only between a glass slide and cover
slip,22 was common and highly selective utilizing
ethylene/vinyl acetate copolymers and oxidized
polyethylene from ethyl acetate, methanol, acet-
onitrile, and 2-propanol solutions.28 Although
transformation to other polymorphs may occur
upon standing, many isolated crystals are indefi-
nitely stable at ambient conditions allowing full
characterization of pure material by Raman and
FTIR spectroscopies, PXRD, DSC, and thermo-
microscopy. Characteristic Raman shifts at 207,
228, 295, 415, 454, 483, 1134, 1294, and 1517 cm1
and absorbances in the FTIR at 571, 696, 765,
1131, 1331, 1700, and 1714 cm1 were observed.
PXRD shows identifiable peaks at 2u¼ 8.9, 15.8,
17.0, 18.5, 19.4, and 22.28. Single plate-like
crystals of form III were obtained by evaporation
of an ethyl acetate solution in the presence ofJOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 96, NO. 11, NOVEMBER 20oxidized polyethylene. The single crystal struc-
ture of form III was solved (Fig. 4b) in the
monoclinic space group P21/c with a¼ 5.7214(9),
b¼ 38.715(6), c¼ 5.9808(10) Å, b¼ 111.655(2)8,
V¼ 1231.3(3) Å3, Z¼ 4. Analysis of the structure
reveals identical dimerization of enantiomers
through the carboxylic acid group and a similar
molecular conformation as observed in the crystal
structure of form I,25 except that the position of
the fluorine atom is disordered over two positions
related by a 1808 rotation of the fluorine sub-
stituted ring. The packing arrangement of
form III is such that a 2.43 Å short C–HF
contact is observed between adjacent molecules
when the fluorine is in the higher occupancy
position.29 A different C–HF interaction of 2.27
Å also exists for the lower occupancy position of
the disordered fluorine. Additionally, two C–HO
interactions exist at 2.59 and 2.66 Å that, when
taken together with the other intermolecular
interactions, create sheets of dimers.
It was found that bulk quantities of form III
could be produced from the melt on polypropylene
in about 50% of crystallizations, which allowed for
the first full characterization of this polymorph as
pure material. DSC reveals an exothermic poly-
morphic transition of 2.9(1) kJ/mol to form I
between 50 and 708C. This is consistent with
thermomicroscopy experiments where the trans-
formation is observed between 55 and 908C.
Raman spectroscopic analysis of the transformed
material confirmed the identity of form I along
with the appropriatemelting point in the DSC and
hot-stage experiments. Therefore, based on the
heat-of-fusion and heat-of-transition rules,27
forms I and III are monotropically related; forms
II and III are also monotropically related based on
the heat-of-fusion rule.
The fourth unique Raman spectrum observed
was found with crystals grown from methanol
in the presence of poly(n-butyl methacrylate),
polycaprolactone, chlorinated polyethylene, and07 DOI 10.1002/jps
Figure 4. Packing diagrams of (a) form I, (b) form III,
and (c) hydrate of flurbiprofen.
NEW FORM DISCOVERY FOR FLURBIPROFEN AND SULINDAC 2983styrene butadiene ABA block copolymer as well as
the sodium salt of alginic acid and poly(vinyl
alcohol) from evaporation of ethanol solutions.
The distinguishing peaks in the Raman spectrum
were observed at 225, 257, 293, 396, 413, 479,
1131, 1295, and 1515 cm1. PXRD indicated a new
crystalline phase with diffraction lines at 2u¼ 5.0,
16.7, 18.2, 18.7, 20.8, 22.4, and 30.78. Heating of
this form on the hot stage reveals a broad
transition between 50 and 908C, which is found
to be a transformation to form I, as verified by
Raman microscopy. Moreover, this transition to
form I occurs at room temperature when the
crystals are allowed to stand for several days and
is accelerated upon grinding with KBr and
pressing a pellet, which precluded obtaining FTIRDOI 10.1002/jps JOURNAdata. Single crystals were grown by slow evapora-
tion (2 days) of an ethanol solution in the
presence of the sodium salt of alginic acid and
the structure was determined (Fig. 4c). It revealed
an unprecedented hydrated FBP form with
3:2 FBP:H2O stoichiometry that crystallizes in
the rhombohedral space group R3 with the
following unit cell parameters: a¼ b¼ 33.589(3),
c¼ 5.8932(7) Å, V¼ 5757.9(9) Å3, Z¼ 18. TGA
data show a mass loss of 4.9(1)%, in agreement
with the FBP:H2O ratio observed in the crystal
structure. The water molecules, which are dis-
ordered in the structure model, reside in channels
formed by six FBP molecules. Hydrogen bonding
from the carboxylic acid donor to the oxygen of a
water is apparent with a distance of 2.29 Å and,
although hydrogens on the water molecules are
not resolved in the structure, OO distances of
2.58 Å to the carbonyl and 2.72 Å to the oxygen of
the acid indicate the presence of additional
hydrogen bonds. The crystallization of this form
occurredmore frequently with addition of water to
FBP solutions in the presence of polymers.
However, in the absence of polymers it was not
observed upon evaporation of methanol solutions
containing added water. Furthermore, when FBP
hydrate is stirred in an aqueous solution that is
saturated with respect to form I, the hydrate
transforms to form I. Therefore, this hydrate is not
stable to water.Sulindac
SUL was crystallized in the same manner as FBP
in the presence of a diverse polymer library from a
variety of solvents. Many common solvents favor
the formation of form II with room temperature
evaporation, but 73% of crystallizations from
acetone solution in the presence of polymers
and several crystallizations from methanol solu-
tions in the presence of Nylons, polyamide resin,
styrene/ethylene-butylene ABA block copolymer,
and carboxylated vinyl chloride/vinyl acetate
copolymer resulted in the nucleation of form I.
Large quantities of form I were also obtained by
sublimation. This form was identified by its
distinctive PXRD pattern (Fig. 5, Tab. 1) with
diffraction lines at 2u¼ 7.1, 10.7, 13.0, 18.5, 19.8,
and 26.48, Raman spectrum (Fig. 6) with shifts at
192, 225, 283, 306, 395, 438, 869, 1182, and
1211 cm1 and FTIR peaks at 871, 1008, 1023,
1403, 1602, and 1713 cm1. The melting behavior
of this form23,24 consists of a singlemelt at 191.08CL OF PHARMACEUTICAL SCIENCES, VOL. 96, NO. 11, NOVEMBER 2007
Figure 7. DSC thermograms of forms I, II, and IV of
sulindac.
Figure 5. PXRD patterns of forms I, II, and IV of
sulindac.
2984 GRZESIAK AND MATZGERon the hot stage. DSC revealed an onset of melting
at 190.6(2)8C with an enthalpy of melting of
27.6(1) kJ/mol (Fig. 7, Tab. 2). Evaporation of
methanol solutions in the presence of Nylon 6/9,
Nylon 6/10, and styrene/ethylene-butylene ABA
block copolymer yielded plate-like single crystals
of form I suitable for structure determination by
X-ray diffraction. This form was found to crystal-
lize in the monoclinic space group P21/c with
a¼ 12.645(3), b¼ 7.8887(17), c¼ 17.788(4) Å,
b¼ 104.879(3)8, V¼ 1714.9(6) Å3, Z¼ 4. Analysis
of the structure of form I reveals hydrogen
bonding from the carboxylic acid to the sulfone
with a distance of 1.77 Å, which is similar to that
found in form II (Fig. 8). Additionally, there is a
short C–HF contact of 2.39 Å and three C–HO
contacts of 2.50, 2.56, and 2.62 Å that, when taken
together, create a three-dimensional network of
hydrogen bonding.
Blade morphology form II crystals, which are
the commercial form of SUL, were the major
product crystallized from most solvents utilized,
particularly methanol, ethanol, and 2-propanol.
Form II has a characteristic Raman spectrumFigure 6. Raman spectra of forms I, II, and IV of
sulindac.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 96, NO. 11, NOVEMBER 20with peaks at 173, 208, 236, 289, 393, 416, 433,
878, 1188, and 1211 cm1 as well as FTIR peaks at
879, 1007, 1019, 1407, 1589, 1603, and 1701 cm1.
It also has distinctive peaks at 2u¼ 9.6, 14.0, 18.5,
21.4, 24.0, and 24.98 in the PXRD pattern. The
melting point of form II was found to be 187.58C on
the hot stage and DSC showed an onset of melting
at 185.6(1)8C and an enthalpy of melting of 31.1(1)
kJ/mol, which is in agreement with previously
reported data.23,24 This indicates an enantiotropic
relationship between SUL forms I and II.
Notably absent was form III, which was never
produced utilizing the polymer-induced hetero-Figure 8. Packing diagrams showing hydrogen
bonding in (a) form I and (b) form II of sulindac.
07 DOI 10.1002/jps
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However, there was the appearance of needle-
shaped crystals with characteristic Raman shifts
at 180, 274, 310, 337, 401, 431, 865, 1181, and
1207 cm1 from crystals grown by evaporation of
methanol and 2-propanol in the presence of
chlorinated polyethylene (42% Cl). The selectivity
for this form was greater than 95% in crystal-
lizations from methanol solutions using these
conditions, but single crystals were not obtained.
FTIR shows distinguishing peaks at 861, 1012,
1027, 1401, 1602, and 1711 cm1. TGA data
showed nomass loss prior to 2408C indicating that
there was no solvent in the lattice. Data from
PXRDwith identifiable peaks at 2u¼ 6.2, 7.6, 13.3,
15.3, 16.5, and 22.28 do not match any known
patterns proving that this is indeed a new
polymorph of SUL (form IV). Upon heating form
IV at 58C/min on the hot stage, it melts and
partially recrystallizes to a new form between
140 and 1608C. The newly crystallized form
subsequently melted at 1898C, consistent with
transformation to form I. Raman spectroscopy of
form IV that was heated to 1708C to allow the
transformation confirmed that form I had crystal-
lized. This broad transition was also seen in DSC
experiments and integration of the form I peak
indicates incomplete transformation. DSC also
revealed that enthalpy of melting of form IV is
21.4(18) kJ/mol, which establishes a monotropic
relationship between forms I and IV and also
between forms II and IV based on the application
of the heat-of-fusion rule.27CONCLUSION
Polymer-induced heteronucleation methodology
has been demonstrated to selectively crystallize
polymorphs of the extensively studied pharma-
ceuticals FBP and SUL. This approach facilitated
the growth of single crystals and subsequent
structure determination of two polymorphs that
were grown directly from polymers, a result that is
highly desirable for unambiguous and accurate
characterization of polymorphs. A new polymorph
of SUL was also discovered through the applica-
tion of this technique and its scale-up was
achieved by conditions identified through high-
throughput screening experiments. Furthermore,
the selective growth of a new hydrate of FBP,
which could not be produced in the absence of
added polymers even with added water in solu-
tion, was achieved. These findings indicate thatDOI 10.1002/jps JOURNAthe polymer-induced heteronucleation approach
is of great utility not only for pure compounds
but also for multicomponent crystalline solids as
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